Bibliografia UJ CM

1/3
Keith Holmes, Ulrike Potschger, Andrew D.J. Pearson, Sabine Sarnacki, Giovanni Cecchetto, Javier Gomez-Chacon, Roly Squire, Enrique Freud, Adam Bysiek, Lucas E. Matthyssens, Martin Metzelder, Tom Monclair, Jakob Stenman, Michal Rygl, Lars Rasmussen, Jean-Marc Joseph, Sabine Irtan, Stefano Avanzini, Jan Godzinski, Kristin Bjornland, Martin Elliott, Roberto Luksch, Victoria Castel, Shifra Ash, Walentyna Balwierz, Genevieve Laureys, Ellen Ruud, Vassilios Papadakis, Josef Malis, Cormac Owens, Henrik Schroeder, Maja Beck-Popovic, Toby Trahair, Ana Forjaz De Lacerda, Peter F. Ambros, Mark N. Gaze, Kieran McHugh, Dominique Valteau-Couanet, Ruth Lydia Ladenstein.
Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma : A Report From the HR-NBL1/SIOPEN Study.
Journal of Clinical Oncology
2020 : Vol. 38, nr 25, s. 2902-2915
Autor korespondencyjny: Ruth Lydia Ladenstein.
p-ISSN: 0732-183X
AZ
ORG
AIF
IF: 44.544
Adres url:
Streszczenie w PubMed:
DOI:
2/3
Ruth Lydia Ladenstein, Ulrike Poetschger, Dominique Valteau-Couanet, Juliet Gray, Roberto Luksch, Walentyna Balwierz, Victoria Castel, Shifra Ash, Maja Beck Popovic, Genevieve Laureys, Godfrey Chi-Fung Chan, Ellen Ruud, Kim Vettenranta, Cormac Owens, Henrik Schroeder, Peter F. Ambros, Sabine Sarnacki, Tom Boterberg, Holger N. Lode.
Risk factors in the HR-NBL-1/SIOPEN study in patients receiving dinutuximab beta (DB) based immunotherapy.
Journal of Clinical Oncology
2020 : Vol. 38, nr 15 suppl., abtr. 10536
2020 ASCO Annual Meeting I.
p-ISSN: 0732-183X
SZZ
SIF
Adres url:
3/3
Lydia Ruth Ladenstein, Ulrike Poetschger, Dominique Valteau-Couanet, Juliet Gray, Roberto Luksch, Walentyna Balwierz, Victoria Castel, Shifra Ash, Maja Beck Popovic, Genevieve Laureys, Godfrey Chi Fung Chan, Ellen Ruud, Kim Vettenranta, Cormac Owens, Henrik Schroeder, Hans Loibner, Peter F. Ambros, Sabine Sarnacki, Tom Boterberg, Holger N. Lode.
Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with anti-GD2 antibody dinutuximab beta (DB) long-term infusion (LTI) in front-line high-risk neuroblastoma patients: Early results from the HR-NBL1/SIOPEN trial.
Journal of Clinical Oncology
2019 : Vol. 37, nr 15, suppl., abstr. 10013
2019 ASCO Annual Meeting I.
p-ISSN: 0732-183X
SZZ
SIF
Wyświetl ponownie stosując format:

Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka Medyczna UJ